Single-Dose Study of a New Formulation of BIIB061
Completed · Phase 1
Conditions studied: Multiple Sclerosis
In brief
The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061 in the new oral formulation in the fasted state in healthy male and female volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BIIB061 in the new formulation in this study population.
Key facts
- Study ID
- NCT02521545
- Run by
- Biogen
- People needed
- 8
- Starts
- 2015-07-01
- Expected to finish
- 2015-08-01
- Last updated by the study team
- 2015-09-07
Who can join
Age: 20 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.